13.1 Authorisations The Issuer shall, and shall procure that each other Group Company will, in all material respects obtain, maintain and comply with the terms of any authorisation, approval, license and consent required for the conduct of its business as carried out at the date of these Bond Terms if a failure to do so would have Material Adverse Effect.
13.3 Continuation of business The Issuer shall ensure that no material change is made to the general nature of the business carried on by the Group as of the Issue Date (and for the avoidance of doubt, any extension of the business of the Group into businesses similar or complementary to the business previously conducted, shall not constitute a material change for the purposes of this undertaking).
13.4 Corporate status The Issuer shall not change its type of legal organisation or jurisdiction of incorporation.
13.5 Insurance The Issuer shall, and shall ensure that all other Group Companies will, maintain insurances or captive arrangements on and in relation to its business and assets against those risks and to the extent as is usual for companies carrying on the same or substantially similar business.
13.6 Mergers The Issuer shall not, and shall ensure that no other Group Company shall, carry out any merger or other business combination or corporate reorganisation involving a consolidation of the assets and obligations of the Issuer or any other Group Company with any other companies or entities, if such transaction would have a Material Adverse Effect.
26 (46)
13.7 De-mergers
The Issuer shall not, and shall make sure that no Group Company shall, carry out any de merger or other corporate reorganisation involving splitting the Issuer or any such Group Company into two or more separate companies or entities, if such transaction would have a Material Adverse Effect. The Issuer shall notify the Trustee of any such transaction, providing relevant details thereof, as well as, if applicable, its reasons for believing that the proposed transaction would not have a Material Adverse Effect.
13.8 Acquisitions
